Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 3Phase 3 2Phase 2 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1Breast 1

Conditions

Neoplasm Metastasis 1Gastrointestinal Stromal Tumors 1Breast Neoplasms 1

Interventions

pembrolizumab 130Carboplatin 127Cisplatin 118Paclitaxel 99Gemcitabine 87Specimen Handling 80Magnetic Resonance Spectroscopy 80Docetaxel 70Dexamethasone 62Cyclophosphamide 61Pemetrexed 59Capecitabine 56Bevacizumab 56durvalumab 52Oxaliplatin 52Fluorouracil 50Doxorubicin 49Radiotherapy 48Leucovorin 45Radiation 44Rituximab 43Lenalidomide 42Vincristine 39Etoposide 36Nivolumab 34atezolizumab 33Letrozole 32130-nm albumin-bound paclitaxel 32Irinotecan 31Prednisone 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Midazolam × 90 days × Clear all
NCT05208047 2026-05-22

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Cogent Biosciences, Inc.

Phase 3 Active not recruiting
482 enrolled
GastrointestinalSarcoma

Neoplasm Metastasis, Gastrointestinal Stromal Tumors

NCT05646862 2026-05-06

INAVO121

Hoffmann-La Roche

Phase 3 Active not recruiting
420 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡